Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 51

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 51
---
000 Ordinary Shares subject to outstanding stock options which 
 are exercisable at November 1, 2025 or will become exercisable within 60 days after such date.           |

| (5) | Shares owned by Dr. de Vries are Ordinary Shares subject to outstanding stock options which are exercisable 
 at November 1, 2025 or will become exercisable within 60 days after such date.                              |

| (6) | Shares owned by all directors and senior management as a group include 100,632,375 Ordinary Shares subject                         
 to outstanding stock options, which are exercisable at November 1, 2025 or will become exercisable within 60 days after such date. |

As of November 1, 2025, approximately 0.0008%
of our outstanding Ordinary Shares was held by registered shareholders with addresses in the United Kingdom, and we had 186 holders of
record in the United Kingdom (in each case, excluding shares held by the custodian under our depositary agreement with JPMorgan Chase
Bank, N.A.). As of November 1, 2025, JPMorgan Chase Bank, N.A., as depositary for the Depositary Shares, held 61,658,852,427 Ordinary
Shares, representing approximately 99.5% of the issued share capital held at that date. As of November 1, 2025, we had three holders of
record with an address in the United States. The number of holders of record or registered holders in the United States or United Kingdom
is not representative of the number of beneficial holders or of the residence of beneficial holders.

Based on our share register,
we believe that we are not directly or indirectly controlled by another corporation or government, or by any other natural or legal persons.
There are no arrangements that may result in a change of control. Our major shareholders do not have different voting rights than other
holders of our Ordinary Shares.

To our knowledge, other than
due to the expiration of unexercised warrants held by our shareholders or as otherwise disclosed elsewhere in, or incorporated by reference
into, this prospectus, there has been no significant change in the percentage ownership of our Ordinary Shares held by the principal shareholders
listed above in the last three years.

| 33 |

<div align='center'>DESCRIPTION OF SECURITIES WE ARE OFFERING</div>

We are offering Units, each
Unit consisting of one Depositary Share and one Series L Warrant to purchase one Depositary Share.